Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 230
Tipo Título / Nombre Autor(es) Año
Clinical Features and Treatment in Patients Diagnosedwith Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema EpidemiologicRegistry (EPI-BLAS study) Navarro Vicente I, Lloret Madrid P. Solana-Altabella A..., Bergua Burgues JM 2023
A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial Bergua Burgues JM, Tarazona R, García Casado J, Gordillo JJ, Casas Aviles I, Rodríguez Veiga R, Cano I 2023
Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Olszewski AJ, Eradat H, Avigdor A, Horowitz NA..., Bergua Burgues JM 2023
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety Moreno AF, Lavín-Alconero L, de Ugarriza PL, Blanco LS, Hernández SC, Burgués JMB 2023
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330) Rosenberg A, Baljevic M, Alegre Amor A..., Bergua Burgues JM 2023
COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330) Ravandi F, Lancet J..., Bergua Burgues JM 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B..., Bergua JM 2023
Feasibility and outcome after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia. Results of the BURKIMAB14 trial Ribera JM, Morgades M, García Calduch O..., Bergua Burgues JM 2023
Midostaurin plus 7+3 in FLT3-ITD mutated AML Torno M, Día Beya M, Fenández Moreno A..., Bergua Burgues JM 2023
Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience Sobas M, Knopinska-Posluszny W, Bergua Burgues JM, Rodríguez-Veiga R, Cano Ferri I..., Montesinos P 2023